Sunday, June 22, 2025 6/22/2025

Optical imaging of pancreas cancer organoids for drug development and personalized treatment

Award Number: R01CA211082
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2017
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Optical imaging of pancreas cancer organoids for drug development and personalized treatment - Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and poorly understood disease that has the worst prognosis of all cancers (5 year survival of 7%), with more than 40,000 deaths per year in the US. Standard- of-care treatment for PDAC includes surgery and chemotherapy. Many patients receive chemotherapy after surgery (“adjuvant treatment”), to improve progression-free survival. About 45-55% of patients present with metastatic disease and immediately begin chemotherapy if tolerated. Unfortunately, there are significant toxicities associated with chemotherapy, and there are no tools to determine whether a patient will benefit from a more toxic versus a less toxic drug. Additionally, there is no rational system to match each patient with the most promising new drug for their cancer. Finally, there are few effective drugs for PDAC, and therefore a demand for accelerated drug development. Thus, there is a critical need to improve the care of PDAC patients through reduced toxicities, rational treatment planning, and new drug development. The goal of this proposal is to develop novel cellular-level imaging technologies to predict treatment response in individual PDAC patients, using macro-suspensions of the patients’ tumors maintained in a 3D culture (“organoids”). This non-invasive optical metabolic imaging (OMI) approach exploits the intrinsic fluorescence intensity and lifetime of the metabolic co-enzymes NADH and FAD to image drug response on a single-cell level across all cells in the intact 3D sample. This single-cell analysis allows for heterogeneous drug response to be monitored over a treatment time-course in tumor cells and stromal cells. This is important for assessing treatment efficacy in the highly heterogeneous and stromal micro-environment of PDAC. The use of primary tumor organoids derived from the patients’ own tumor also maintains the cell-cell communication, 3D architecture, and tumor-stromal interactions that are critical to accurately assess drug response. Our preliminary data indicate that OMI in primary PDAC organoids (1) accurately predicts in vivo drug response in mice, and (2) can identify drugs that effectively target tumor fibroblasts for stromal re-organization and improved drug delivery. We have also established feasibility for human testing in 6 PDAC patients. This novel platform provides great potential for (1) rapidly testing new drug regimens on relevant patient samples, thus accelerating PDAC drug development, and (2) providing individualized drug screens to identify the most effective and least toxic treatment for each patient. This proposal will test the hypothesis that OMI of primary PDAC organoids can accurately predict in vivo treatment efficacy in mice and humans. This approach will be validated on mouse models of PDAC, on primary patient samples in the adjuvant treatment setting, and on primary patient samples in the metastatic treatment setting. The proposed development of dynamic, single-cell assessment techniques to monitor drug response in multiple cell types within intact mouse and human PDAC organoids holds great promise for rational drug development and treatment planning that could ultimately reduce toxicities and improve outcomes in patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$5 )
2024	2021	THE MORGRIDGE INSTITUTE FOR RESEARCH, INC.	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	5	2/28/2024	NON-COMPETING CONTINUATION	-$5
														Subtotal = -$5

Issue Date FY: 2021 ( Subtotal = $554,862 )
2021	2021	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	5	7/13/2021	NON-COMPETING CONTINUATION	$554,862
														Subtotal = $554,862

Issue Date FY: 2020 ( Subtotal = $790,207 )
2020	2020	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	4	7/24/2020	NON-COMPETING CONTINUATION	$790,207
														Subtotal = $790,207

Issue Date FY: 2019 ( Subtotal = $857,849 )
2019	2019	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	3	6/20/2019	NON-COMPETING CONTINUATION	$611,452
2019	2019	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	001	3	6/21/2019	SUPPLEMENT FOR EXPANSION	$246,397
														Subtotal = $857,849

Issue Date FY: 2018 ( Subtotal = $630,364 )
2018	2018	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	2	7/17/2018	NON-COMPETING CONTINUATION	$630,364
														Subtotal = $630,364

Issue Date FY: 2017 ( Subtotal = $648,387 )
2017	2017	MORGRIDGE INSTITUTE FOR RESEARCH, INC., THE	330 N ORCHARD ST	MADISON	WI	53715	DANE	USA	Cancer Detection and Diagnosis Research	000	1	7/27/2017	NEW	$648,387
														Subtotal = $648,387

Grand Total All Awards = $3,481,664

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optical imaging of pancreas cancer organoids for drug development and personalized treatment

Award Number: R01CA211082

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2017

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer